Inspire Medical Systems, Inc.

Fundamentals7.5
Price Action6.0
News Sentiment5.5
AI Rating
6.0

Key Drivers

  • Margin Strength
  • Expense Pressure
  • Strong Liquidity

AI
AI Summary

6.0

INSP remains a financially resilient medtech franchise with strong cash flow and margins, but the stock now depends on Inspire V launching cleanly and reaccelerating revenue fast enough to offset reimbursement/coding friction and rising execution scrutiny, making it a “show-me” story rather than a clean compounder from here.

BalanceSheet
Execution
Reimbursement‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

7.5

Key Financial Insights:

  • Margin Strength
  • Expense Pressure
  • Strong Liquidity

INSP shows strong profitability, liquidity, and low leverage, but heavy operating and stock-based compensation expenses continue to pressure earnings and can quickly erase operating profit.

HighMargins
ExpensePressure

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Higher lows
  • Resistance breakout
  • Mid-$40s hold

INSP's short-term trend has turned constructive after breaking above the June range and the $45–$46 resistance zone, but it needs to hold the mid-$40s to keep the rebound intact.

INSP
breakout
Support Level: $43.00-$44.00
Resistance Level: $45.00-$46.00

Choppy trading from late

Sentiment & News

5.5

Key News Insights:

  • Coding disruption
  • SLEEP 2026
  • Launch scrutiny

Inspire Medical's June headlines point to a temporary revenue disruption from coding/CMS issues, offset by strong liquidity and continued clinical-commercial momentum, while delayed Inspire V disclosures add governance scrutiny.

Liquidity
MedTech

The mix of product momentum and operational questions likely keeps sentiment cautious near term, but the strong balance sheet supports the longer-term thesis